Skip to content
AnalystLens

ELI LILLY & Co 8-K Report, Corporate Update (Aug 20, 2025)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed August 20, 2025
Period End
August 18, 2025
Security
LLY
In the record · 2016–202610-K1110-Q328-K110

LLY filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 110 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Mar ’19Mar ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’24Sep ’24

Summary

Summary of the 8-K filed August 20, 2025. Cited figures are marked; the original filing is the authoritative source.

Eli Lilly and Company (LLY) has announced the successful completion of a significant debt offering, raising approximately $6.71 billiona in net proceeds after underwriting discounts and before expenses.

This capital raise involves the issuance of multiple tranches of notes, including $750 millionb in Floating Rate Notes due 2028 and various fixed-rate notes with maturities ranging from 2028 to 2065. The fixed-rate notes carry coupon rates from 4.000% to 5.650% per annum, while the floating-rate notes are tied to Compounded SOFR plus a spread. This substantial debt issuance is likely intended to support Eli Lilly's ongoing research and development efforts, potential acquisitions, or to strengthen its balance sheet.

The diversity in note maturities and the inclusion of floating-rate notes suggest a strategic approach to managing interest rate risk and financing its long-term growth initiatives. Investors should monitor how these proceeds are deployed and their impact on the company's financial leverage and future profitability.

Key Highlights

  1. Eli Lilly & Co. successfully closed a debt offering, raising approximately $6.71 billion in net proceeds.
  2. The offering included $750 million in Floating Rate Notes due 2028, with interest tied to Compounded SOFR plus 0.530%.
  3. Several series of fixed-rate notes were issued, totaling $6 billion, with maturities ranging from 2028 to 2065.
  4. Fixed-rate notes carry annual interest rates from 4.000% to 5.650%.
  5. The issuance was registered under a Form S-3 registration statement (File No. 333-285052).
  6. The company entered into an underwriting agreement with a syndicate of major financial institutions.
  7. The notes are governed by an Indenture dated February 1, 1991, with Deutsche Bank Trust Company Americas as trustee.

Frequently Asked Questions

  1. What is the total amount Eli Lilly raised from this debt offering?

    Eli Lilly and Company realized approximately $6.71 billion in net proceeds from the offering, after deducting underwriting discounts and before estimated offering expenses.

  2. What types of notes were issued and what are their maturity dates?

    The company issued $750 million in Floating Rate Notes due October 15, 2028. Additionally, fixed-rate notes were issued with principal amounts and maturities as follows: $1 billion of 4.000% Notes due October 15, 2028; $750 million of 4.250% Notes due March 15, 2031; $1 billion of 4.550% Notes due October 15, 2032; $1.25 billion of 4.900% Notes due October 15, 2035; $1 billion of 5.550% Notes due October 15, 2055; and $1 billion of 5.650% Notes due October 15, 2065.

  3. How is interest calculated on the Floating Rate Notes?

    The Floating Rate Notes accrue interest at a rate that resets and is payable quarterly. The rate is equal to Compounded SOFR plus a spread of 0.530%.

  4. What are the primary purposes of this debt issuance?

    The filing does not explicitly state the purpose of the debt issuance. However, such substantial capital raises are typically used to fund research and development, potential mergers and acquisitions, capital expenditures, or general corporate purposes to support ongoing operations and growth initiatives.